Follistatin-344

Follistatin-344 (FS-344) is a natural signalling protein that, in animal experiments, dramatically increases skeletal-muscle mass. It is one of several slightly different versions (isoforms) of follistatin that the body produces, and it is the specific form used in clinical gene-therapy programmes. The ambition behind FS-344 is to neutralise muscle-growth brakes like myostatin and activin A. However, the picture in humans is very limited: the only published clinical data come from small gene-therapy trials in patients with muscle-wasting diseases - not from the injectable peptide sold on the internet. Below we explain what is actually known, how strong the evidence is, and what the risks and legal status are.

What is Follistatin-344?

Follistatin-344 (FS-344) is a naturally occurring signalling molecule that, in animal experiments, dramatically increases skeletal-muscle mass by removing a central biological brake on muscle growth. No pharmaceutical-grade FS-344 formulation is approved anywhere in the world, and the only human evidence comes from gene-therapy vectors, not from the free peptide.

In technical terms: FS-344 is a 344-amino-acid version (a so-called isoform) of a natural protein called follistatin that functions as a potent antagonist of myostatin (GDF-8), activin A, and other members of the TGF-β family of signalling molecules. Follistatin comes in several slightly different versions (isoforms) that the body makes from the same gene by a process called alternative splicing (the gene is cut and recombined in different ways); FS-344 is the longest form (344 amino acids) and is the variant encoded in the rAAV1.CMV.huFollistatin344 construct used in clinical trials. A closely related isoform, FS-315, is also discussed in the grey market, but the clinical pipeline is built around FS-344.

It is important to separate three things that are often conflated online: (1) endogenous follistatin, which the body makes itself; (2) AAV1-FS344 gene therapy, where a viral vector delivers the genetic blueprint so that muscle cells produce FS-344 themselves over a long period; and (3) lab-made recombinant FS-344 peptide sold as a "research chemical," which is injected directly. Only the first two have any grounding in legitimate science - the third has no published human pharmacokinetic data (that is, information on how the substance is absorbed, distributed and broken down in the body), nor any dosing or safety data.

How does Follistatin-344 work?

Follistatin-344 acts by directly binding and neutralising several ligands of the TGF-β superfamily (a large group of the body's own signalling molecules that control growth, inflammation and tissue repair), primarily myostatin (GDF-8), activin A, activin B, and selected bone morphogenetic proteins (BMPs); this broader blockade differentiates it from selective myostatin-only inhibitors and shifts skeletal-muscle turnover toward hypertrophy (muscle growth and enlargement) and regeneration. Myostatin is the body's central negative regulator of skeletal-muscle mass - effectively a "brake" that prevents muscle from growing beyond a set point. By sequestering this brake, FS-344 removes the limit on fibre growth.

Crucially, FS-344's mechanism is broader than a pure myostatin inhibitor. Activin A is also involved in inflammation and muscle catabolism (muscle breakdown), and blocking it produces additive effects in animal models, including reduced inflammation in models of blood poisoning (endotoxaemia). In direct preclinical comparisons, FS-344 produced greater muscle enlargement in the quadriceps and tibialis anterior than related binding proteins such as FLRG or GASP-1, which also inhibit myostatin but have a narrower ligand spectrum. This breadth is simultaneously FS-344's promise and its main safety concern: interfering with multiple TGF-β-family pathways can have unpredictable unintended side-effects on tissues beyond skeletal muscle (so-called off-target effects).

How effective is Follistatin-344?

The efficacy picture for Follistatin-344 is sharply split between dramatic animal results and very thin human data: transgenic mice and AAV1-FS344-injected mice showed muscle-mass increases of 194 to 327 %, non-human primates showed measurable gains in muscle cross-sectional area and strength, but the only published human trial (Becker muscular dystrophy, six patients) produced mixed functional outcomes after one year, with some patients walking better and others showing no improvement. No human efficacy data exist for the injectable peptide form sold online.

In the animal literature, the effects are striking. In direct comparisons, FS-344 outperformed the related binding proteins FLRG and GASP-1 in increasing quadriceps and tibialis-anterior mass. The AAV1-FS344 gene-therapy vector was well tolerated in mice for more than two years, providing at least one long-term safety signal - though in mice, not humans. In non-human primates, a single intramuscular administration of AAV1-FS344 produced measurable increases in muscle size and strength, supporting the biological plausibility of the approach.

In humans, the evidence is confined to the gene-therapy programme. The Becker-MD Phase 1/2a study (Mendell et al., 2015) tested a single intramuscular injection of rAAV1.CMV.huFollistatin344 into the quadriceps of six patients. After a one-year follow-up, results were mixed: some patients showed improvements in walking, others did not. A follow-up study (NCT02354781) extended the approach to six Duchenne-MD patients. These are safety-focused trials in severely ill patients, not efficacy trials in healthy athletes, and they tell us nothing about dosing or effects of the free peptide.

The AAV1-FS344 study programme

The only structured human research programme for FS-344 is the AAV1-FS344 gene-therapy programme led by Jerry Mendell at Nationwide Children's Hospital, which delivered a viral vector carrying the FS-344 gene directly into muscle tissue of patients with muscular dystrophy. Three indications were explored: Becker muscular dystrophy, Duchenne muscular dystrophy, and sporadic inclusion body myositis (a rare inflammatory muscle-wasting disease). No parallel programme exists for the free injectable peptide.

The Becker-MD trial (six patients, one-year follow-up, published in Molecular Therapy, 2015) provided the first and so far only published human dataset. It reported a mixed functional picture and an acceptable short-term safety profile for focal intramuscular gene delivery. The Duchenne follow-up (NCT02354781) extended recruitment to six DMD patients, using the same vector construct. These trials test local injection into a single weakened muscle (the quadriceps or biceps) under clinical supervision - they do not, and were not designed to, validate systemic peptide dosing, subcutaneous injection, or performance use in healthy people.

Dosage: what the studies show - and what users do

No validated human dose exists for the injectable FS-344 peptide; the only clinical dosing information comes from AAV1-FS344 gene therapy administered as a single intramuscular injection into the quadriceps or biceps by study staff, and every numerical dosing scheme circulating in bodybuilding forums is an unvalidated anecdote without clinical foundation. No controlled dose-escalation study of free FS-344 peptide has ever been published in humans.

This is a critical gap that is often obscured by confident-sounding online dosing tables. The studies that exist use a gene-therapy vector, not a peptide, and the dose is expressed in vector genomes (vg) per kilogram, not in micrograms of peptide. Any microgram-based dosing schedule for injectable FS-344 in healthy users is extrapolation without evidence. One grey-market source warns that doses above 300 µg may increase the risk of central serous chorioretinopathy - a serious eye condition in which fluid accumulates under the retina, causing blurred vision and visual distortion - and claims a shorter half-life than growth-hormone-releasing peptides such as CJC-1295; these statements are not supported by peer-reviewed human pharmacokinetic data (how the substance is absorbed, distributed and broken down in the body) and should be treated as unverified.

Handling and storage

Because no pharmaceutical-grade FS-344 formulation is approved, there is no officially validated handling, reconstitution, or storage protocol for the peptide sold online; the only context in which storage recommendations appear is the grey-market "research chemical" literature, where refrigeration at 2 to 8 °C is typically advised for freeze-dried powder (called lyophilised powder). Any user encountering FS-344 in this form should understand that storage conditions, sterility, and even identity of the contents are uncontrolled.

In normal pharmacy use, a drug comes with instructions for how to mix and store it. FS-344 has none of that - it is sold as a freeze-dried powder that buyers are expected to mix themselves with sterile water (this step is called reconstitution), with no official guidance on water type, concentration or sterile technique. This makes every step - solvent choice, concentration, sterility, dosing accuracy - an unguided operation on a substance whose purity is often not what the label claims.

Side effects and common mistakes

Safety data for the free FS-344 peptide in humans are essentially absent, and the theoretical risks of broad TGF-β blockade - including irreversible muscular hypertrophy (muscle growth that cannot be naturally reversed) and unintended side-effects on tissues other than skeletal muscle - make this a highly experimental substance; in the gene-therapy context, FS-344 was tolerated in mice for over two years, but this provides limited reassurance for humans using the injectable peptide. Black-market purity data are alarming and are a central harm-reduction concern.

• Not prescribable, not approved: FS-344 is not approved as a medicinal product for humans by any drug regulator worldwide. Every online source is a black-market seller, not a legal pharmaceutical product.
• Black-market quality problems: In a study of 17 products bought as follistatin, only 9 actually contained follistatin - the rest contained wrong peptides, wrong doses, or were contaminated.
• Unvalidated dosing myths: All microgram-based dosing schemes from the bodybuilding world are unverified experience reports without clinical basis, as no human study has ever dosed the free peptide.
• Theoretical off-target risks: The broad TGF-β blockade can affect tissues beyond muscle; irreversible muscle overgrowth and unknown long-term consequences are conceivable.
• Doping trap: Follistatin is on the WADA list and is detectable in blood and urine - athletes risk bans without even knowing whether the product they bought actually contained follistatin.
• Confusion with gene therapy: The clinical trials use a viral vector (AAV1-FS344), not a peptide; conclusions for the injectable peptide are not permissible.

Approval and legal status

Follistatin-344 is not approved as a medicinal product by the European Medicines Agency, the U.S. Food and Drug Administration, or any other major regulator worldwide; it is listed on the WADA Prohibited List under section S4 (Hormone and metabolic modulators), it is detectable in blood and urine via established lab methods that separate the components of a blood or urine sample (electrophoretic methods), and purchase outside of registered clinical trials for human use is illegal. As of the current writing, no country permits FS-344 to be sold as an injectable peptide for human use.

In the EU and Germany, FS-344 falls under the framework of unapproved investigational substances (substances that are only allowed to be handled inside officially registered trials): it may be handled only within registered clinical trials, and commercial supply for self-administration is not permitted. In the USA, the same principle applies - the FDA has not approved any FS-344 product, and the substances sold online as "research chemicals" are not regulated pharmaceuticals. For athletes, WADA's listing is especially relevant: validated detection methods for follistatin exist in both blood and urine, and a positive test carries standard sanctions regardless of whether the product actually contained follistatin. The combined legal, anti-doping, and quality-control picture makes unauthorised use of FS-344 a high-risk decision on every level.